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Abstract
Background: Measles remains a major public health concern in Thailand despite the introduction of vaccination
since 1984. Similar to other countries, Thailand has experienced numerous measles outbreaks including adult
communities such as university student dormitories, prisons, refugee camps, and military recruit camps. These
outbreaks raise questions on the seroprotective antibody level in Thai adults.
Methods: To better understand measles susceptibility in young Thai adults, a retrospective measles seroprevalence
study on repository serum specimens obtained with informed consent from young Thai men entering the Royal Thai
Army (RTA) during 2007–2008 was conducted. A total of 7760 stratified randomized samples were chosen by residence
province. Measles IgG titer was measured using a commercial IgG quantitative ELISA kit following the manufacturer’s
instructions. An antibody level ≥ 250 International Units per Liter (IU/L) was interpreted as seropositive.
Results: The overall measles seroprevalence was 78.5 % (95 % Confidence Interval: 77.6–79.4 %) with geometric mean
titer of 738 IU/L (95 % Confidence Interval: 716–760 IU/L). The measles seroprevalence by province ranged from 59.6 %
to 93.1 %. A trend of decreasing seroprevalence in the younger cohorts despite increasing immunization coverage was
found. Lower seroprevalence than vaccination coverage was observed in the youngest age group.
Conclusions: To achieve long term measles control and elimination, an integrated two doses vaccination strategy has
been implemented in children in Thailand. This nationwide measles seroprevalence study in young adult RTA recruits
found a measles seroprevalence lower than WHO’s recommendation for measles outbreak prevention and elimination.
These results raise concerns for measles control in Thailand. Supplementary immunization in young adults is
essential especially in high-risk and densely populated communities to establish herd immunity for outbreak
prevention and elimination.
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Background
Measles is highly contagious and the cause of mortality
and morbidity with an estimated 74,200 and 37,500
deaths reported annually in Africa and South-East Asia,
respectively. Though measles vaccine has been available
for over 40 years and global deaths reduced from an esti-
mated 2.6 million in 1980 to 145,700 in 2013, measles
remains a public health burden especially in developing
countries. The deaths are primarily in children who are
either unvaccinated or under-vaccinated [1, 2]. However,
measles outbreaks have been sporadically reported in
developed countries with high vaccination coverage
under the two doses vaccine strategy suggesting that
communities of susceptible individuals allows measles
transmission [1].
In Thailand, measles immunizations were started in
9 month olds in 1984 as part of the Expanded Program
on Immunization (EPI) program. One dose measles vac-
cine coverage escalated from 5 % in 1984 to 52 % in
1987 and has exceeded 90 % since 1995 [3, 4]. A second
dose of measles vaccine was added in 1996 for first
grade students and replaced by measles-mumps-rubella
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(MMR) vaccine in 1997. Two dose measles vaccine
coverage has increased from 86 % in 2001 to 94 % in
2014 [4]. The number of reported measles cases in the
Annual Epidemiology Surveillance Report from the
Ministry of Public Health, Thailand, has showed a de-
clined since the start of the vaccination program from
93.67 per 100,000 people in 1984 to 4.10 per 100,000
people in 2013 [3, 5]. The highest incidence reported
in 2013 was in the 0–4 years age group (20.70 per
100,000 people), followed with 5–9 years age group
(7.73 per 100,000 people) and 15–24 years age groups
(6.59 per 100,000 people) [5]. Similar to other countries,
Thailand has experienced numerous measles outbreaks
long after the introduction of vaccination. Measles
outbreaks have been reported in many populations in-
cluding children and adult populations such as school
age children, university students, factory workers,
military recruits, medical staff, and prisoners; thereby,
questioning the seroprotective antibody levels in the
adult Thai population [5–8]. Seroprevalence data in
Thailand from endemic diseases including measles is
limited; the available studies generally cover small
populations [9]. This retrospective study of nationwide
measles seroprevalence was conducted on randomized re-
pository serum specimens from Royal Thai Army (RTA)




Approximately 60,000 young Thai men are selected for
enlistment in the RTA by lottery at the district level an-
nually. Men exempted from the lottery include the
handicapped, certain religious personnel, government
teachers and individuals who complete military instruc-
tion or alternative military service. The selected men are
approximately a 10 % random sample at the district level
of all young Thai men [10]. From a total of 121,370
young men entering the RTA during 2007–2008, 98.4 %
joined a nationwide HIV-1 surveillance program under
informed consent with permission for future studies.
This study was approved by the Institutional Review
Board, Royal Thai Army Medical Department, Bangkok,
Thailand (S066h/52) and approved as exempt by the
Human Subjects Protection Branch, Walter Reed
Army Institute of Research, Washington, DC, USA
(WRAIR#1639). The study was conducted on these
2007–2008 repository serum specimens from young
Thai men aged 18 to 30 years, born between 1977
and 1990. The men aged years 24 and younger by
calculations would have been the first cohort offered
two doses of measles vaccine as part of the EPI in
1984 (first dose) and 1991 (second dose at age of 6),
whereas the men aged 25–30 years were born prior
to the measles vaccination program initiation and
missed the second dose program [3]. Sample sizes
were calculated to detect a seroprevalence of 50 % in
each of the 76 provinces to within 10 % of the true
value with 95 % confidence. A total of 7,760 stratified
randomized samples were chosen on the basis of re-
ported residence province prior to the RTA entry.
Serological test
Measles IgG titer was measured using a commercial IgG
quantitative ELISA kit following the manufacturer’s instruc-
tions (EUROIMMUN, Luebeck, Germany). The standard
curve is obtained by point to point plotting of the extinction
value unit measured for the 4 calibrators against the corre-
sponding unit at 50, 250, 1000 and 5000 international unit
per liter (IU/L). Study sera and kit internal controls were
tested and interpreted according to the manufacturer’s in-
structions where an antibody level equal to or greater than
250 IU/L was interpreted as seropositive. Individual sera
with a value below the cut-off value of 250 IU/L recom-
mended by EUROIMMUN are considered non-infected.
Statistical analysis
Associations between the available demographic charac-
teristics (age, marital status, education level, residential
area and region of residence) and measles seropreva-
lence were tested (Pearson’s chi square) with two-tailed
and p-value < 0.05 considered statistically significant,
analyses were performed using SPSS version 12 (SPSS
Inc; Chicago, Illinois). A spatial distribution map of
measles seroprevalence across Thailand by province of
residence was generated using ArcView 8.3 (ESRI,
Redlands, CA).
Results
The study population is described in the Table 1. The
majority of RTA conscripts were 21 years of age, un-
married, junior high school graduates and lived in
rural areas. The sample size per province ranged from
69–130. The overall IgG measles seroprevalence was
78.5 % (95 % Confidence Interval (CI): 77.6 %–79.4 %)
and geometric mean titer (GMT) was 737.9 IU/L (95 %
CI: 716.4–760.1). The measles seroprevalence by residen-
tial province ranged from 59.6 % to 93.1 %, 31 of 76 prov-
inces had a seroprevalence ≥ 80 % and only 5 provinces
had a seroprevalence ≥ 90 %. Choropleth map of measles
seroprevalence by residential province is shown in Fig. 1.
The measles seroprevalence was lowest in the Northern
region and highest in the Southern region. In the univari-
ate analysis, measles IgG seropositive was significantly as-
sociated with age group, education level and residence
region, but not marital status or type of residence
(Table 1). The measles seroprevalence ranged from 92.4 %
with GMT 1245 (95 % CI: 1036–1497) in the oldest age
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group to 65.8 % with GMT 493 (95 % CI: 437–555) in the
youngest age group. Measles vaccine coverage, measles
seroprevalence and GMT in young Thai men, 2007–2008,
are shown in Fig. 2.
Discussion
This study represents a nationwide seroprevalence
study of measles IgG antibodies in young Thai men.
The overall, by province, and by age cohort measles
seroprevalence in these young men was below the
93–95 % recommended by the WHO for population
immunity [11]. These findings may explain partially
the measles outbreaks occurring in adult populations
in Thailand. Our study is consistent with previous
measles seroprevalence studies conducted in Thailand.
A study of a Thai population sample from the same
birth years (1988–1992) had a similar measles sero-
prevalence [9].
We found significant difference of seroprevalence and
GMT amongst the four regions of Thailand where the
South exhibited the highest and the North the lowest.
Although the geography of the Northern region of
Thailand is mountainous with population scattered
amongst hilly areas [12] whereas the Southern region is
a peninsula between seas with population concentrated
in the coastal areas, with limited regional vaccine cover-
age data in the early years of measles immunization as
well as inconsistent case reporting by region; we cannot
determine why measles seroprevalence is highest in the
Southern region [5, 6, 13].
This study population consists of young Thai men
born as the measles vaccination program was initiated in
Thailand. The measles vaccine coverage ranged from
0 % in the oldest age group born before measles vaccine
program initiation to a reported coverage of 73.0 % in
the youngest age group in Thailand (Fig. 2). The higher
seroprevalence and GMT were found in the oldest age
group was the result of natural infection (born before
vaccination), while the successively lower seroprevalence
and GMT in the younger age groups was from a com-
bination of vaccine induced immunity and natural infec-
tion. However, these observations are limited by lack of
individual measles vaccination and infection history in
this population.
Low seroprevalence of measles antibodies may be from
inadequate vaccine coverage, vaccination failure, or wan-
ing immunity. Inadequate vaccine coverage may be
caused by several factors such as lack of vaccine access,
missed vaccination opportunities, and ignorance of the
importance of vaccination. Vaccination failures may be
Table 1 Measles seroprevalence in association with demographic variables in young Thai men, 2007-2008
Demographic variables Number Testeda Measles seroprevalence (%) (95 % CI)b GMTc (IU/L)d (95 % CI)
Age group (years)e 7673
18–20 1164 70.9 (68.3–73.5) 560 (520–603)
21 5359 78.7 (77.6–79.8) 740 (714–767)
22–24 1005 85.0 (82.8–87.2) 955 (885–1032)
25–30 145 92.4 (88.1–96.7) 1245 (1036–1498)
Marital status 7576
Unmarried 6067 78.2 (77.1–79.2) 733 (709–758)
Married 1509 80.4 (78.4–82.4) 776 (727–829)
Education levele 7743
Primary school and less 2121 79.2 (77.4–80.9) 783 (739–830)
Junior high school 2641 77.7 (76.1–79.3) 706 (672–742)
High school to diploma 2676 77.8 (76.2–79.3) 712 (677–749)
Bachelor 305 86.2 (82.4–90.1) 962 (838–1106)
Residential area 6399
Rural 3896 78.3 (77.0–79.6) 745 (707–785)
Municipal (Urban) 2503 79.3 (77.8–80.9) 739 (709–770)
Region of residencee 7760
North 1738 71.7 (69.6–73.8) 575 (539–613)
Central 2626 79.0 (77.5–80.6) 732 (696–770)
Northeast 2004 79.5 (77.8–81.3) 771 (728–817)
South 1392 84.3 (82.4–86.2) 961 (899–1027)
aNumber in each demographic characteristic does not add to the total number of study samples because of missing data; bCI, confidence interval; c GMT,
geometric mean titer; dIU/L, international unit per liter; e χ2 test statistically significant (Pearson’s chi square, two-sided, p <0.05)
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attributable to the immaturity of the immune system, re-
sidual maternal antibodies, inadequate vaccine dose, or
vaccine inefficacy [14]. The seroprotective level increases
from 85 % in children given first dose vaccine at
9 months to 95 % at 12 months. According to the EPI in
Thailand, children were vaccinated with the first dose of
the measles vaccine at the age of 9 months as recom-
mended by WHO for countries with ongoing measles
transmission; previous serological studies in Thailand
showed that the passive maternal antibody was rapidly
Fig. 1 Choropleth map of measles seroprevalence in young Thai men, 2007–2008. Prevalence is stratified by color and location determined by
reported residence province during the 2 years prior to Royal Thai Army enlistment. Thailand shapefile in the public domain [25]
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lost in infants starting from 4–6 months and almost
completely absent at 8–9 months [15]. A second later
dose may cover the primary non-responders and unvac-
cinated persons who would otherwise accumulate over
time and allow transmission [1]. This may explain why
Thais are still susceptible to measles infection with 40 %
of reported cases found in children of pre-school age
(2009–2013). Recently, the Ministry of Public Health,
Thailand announced that from 2015 onwards the 2nd
dose of vaccination previously given to first graders
(6 years of age) will be given to children at 2.5 years of
age instead [16]. The waning of protective immunity
could pose a risk in communities receiving a single dose
of immunization at a young age without ongoing natural
exposure [17]. A lower measles seroprevalence than vac-
cination coverage found in this study may reflect a com-
bination of waning immunity and measles vaccine
failure in this Thai population. Usually waning immunity
is age related in populations without natural infection or
supplemental vaccinations, but this is not seen in our
study cohort [18].
In Thailand, immunizations are routinely administered
to children regardless of gender and no supplementary
measles immunizations were given to the recruits upon
entering the RTA; this nationwide measles seropreva-
lence study in a sample of Thai recruits selected by lot-
tery at the district level may represent the measles
protective immunity levels in the general young adult
population of the same age groups [3]. Our results show
that approximately 20 % of Thai recruits in 2007–2008
are susceptible to measles; we speculate that females
born in the same years may present similar trends in
measles seroprevalence raising concerns for young Thai
women of reproductive age even through a slightly
higher measles seroprevalence in females has been re-
ported in studies elsewhere [19–21].
With low herd immunity, measles infection can
spread easily in densely populated communities such
as prisons, dormitories, recruit camps and schools.
WHO’s recommendation for immunization coverage
sufficient to reduce measles mortality is ≥90 % at national
level and ≥80 % at every district level. For elimination,
each district must achieve vaccine coverage ≥95 %
through a two-dose vaccination program [11]. In 2001, a
measles outbreak in Bangkok amongst healthcare workers
emphasized the ease of transmission within high-risk adult
populations [7]. A supplementary immunization activity
for higher risk adult communities may be an effective pre-
ventive measure, as implemented in Norway. Even with
the two doses of MMR vaccine at the ages of 15 months
and 12–13 years as part of Norway’s national childhood
immunization program where vaccine coverage was
higher than 95 %, sporadic incidence of measles was still
reported [22, 23]. An additional dose of mump-measles-
rubella vaccine has also been incorporated into the re-
quired vaccination program for military conscripts in
Norway as an outbreak prevention measure [23].
Limitations of this study include a single sample
collection from 2007–2008 in a population of all male
Thai recruits. The lack of information on individual
childhood measles as well as measles vaccination his-
tory and the measles vaccine strains limits the con-
clusions of this study. For future studies, it will be
important to compare seroprevalence data on samples
Fig. 2 Measles vaccine coverage, measles seroprevalence and geometric mean titer (GMT) in young Thai men, 2007–2008. Vaccination coverage
data at 1 year of age from reference 12 by the WHO. Age is reported age in years at time of entry to the Royal Thai Army. Measles seroprevalence
defined as percent with titer >250 International Units per Liter (IU/L) by IgG ELISA
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collected more recently from individuals with documented
immunization histories from several age groups in the
general population to better represent current Thai popu-
lation protective immunity.
Conclusion
This nationwide measles seroprevalence study from
RTA recruits born between 1977 and 1990, found a
measles seroprevalence of 78.5 %, lower than WHO’s rec-
ommendation for measles outbreak prevention and elim-
ination. A trend of decreasing seroprevalence in the
younger cohorts in contrast to increasing immunization
coverage was found. These results raise concerns for
measles control in Thailand as well as meeting the
Southeast Asia plan for measles control and elimin-
ation goal by 2020 [24]. While the two doses
immunization strategy in childhood has been imple-
mented, a supplementary immunization activity in
young adults is essential especially in high-risk and
densely populated communities to establish herd im-
munity for outbreak prevention and ultimately mea-
sles elimination in Thailand.
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